Compounds > ursodeoxycholic acid
Page last updated: 2024-08-23

ursodeoxycholic acid and Diabetes Mellitus, Type 1

ursodeoxycholic acid has been researched along with Diabetes Mellitus, Type 1 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Al-Salami, H; Al-Sallami, H; Arfuso, F; Goločorbin-Kon, S; Kovacevic, B; Luna, G; Mikov, M; Mooranian, A; Stojanovic, G; Zamani, N1
Al-Salami, H; Goločorbin-Kon, S; Ionescu, CM; Kovačević, B; Luna, G; Mikov, M; Mooranian, A; Takechi, R; Zamani, N1
Al-Salami, H; Al-Sallami, H; Arfuso, F; Goločorbin-Kon, S; Kovacevic, B; Mikov, M; Mooranian, A; Takechi, R; Zamani, N1
Gotthardt, DN; Mummelthei, A; Rupp, C; Sauer, P; Schirmacher, P; Stiehl, A; Stremmel, W; Weiss, KH1
Junge, U; Pohl, R1

Other Studies

5 other study(ies) available for ursodeoxycholic acid and Diabetes Mellitus, Type 1

ArticleYear
Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model.
    Pharmaceutical development and technology, 2019, Volume: 24, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Combinations; Drug Compounding; Excipients; Insulin-Secreting Cells; Mice, Inbred BALB C; Particle Size; Probucol; Tissue Distribution; Ursodeoxycholic Acid

2019
Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation.
    Pharmacological reports : PR, 2020, Volume: 72, Issue:2

    Topics: Acrylates; Animals; Bile Acids and Salts; Blood Glucose; Chenodeoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Feces; Insulin; Lithocholic Acid; Mice; Nanoconjugates; Ursodeoxycholic Acid

2020
Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes.
    Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup3

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Intestinal Mucosa; Liver; Mice; Mice, Inbred BALB C; Nanocapsules; Probucol; Ursodeoxycholic Acid

2018
Non-IBD immunological diseases are a risk factor for reduced survival in PSC.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:1

    Topics: Adult; Autoimmune Diseases; Chi-Square Distribution; Cholagogues and Choleretics; Cholangitis, Sclerosing; Diabetes Mellitus, Type 1; Disease-Free Survival; Female; Humans; Inflammation; Kaplan-Meier Estimate; Liver Transplantation; Male; Multivariate Analysis; Prevalence; Proportional Hazards Models; Psoriasis; Retrospective Studies; Risk Assessment; Risk Factors; Sarcoidosis; Tertiary Care Centers; Thyroiditis, Autoimmune; Time Factors; Ursodeoxycholic Acid

2013
[Primary sclerosing cholangitis with chronic pancreatitis].
    Deutsche medizinische Wochenschrift (1946), 1997, Jun-13, Volume: 122, Issue:24

    Topics: Aged; Cholagogues and Choleretics; Cholangitis, Sclerosing; Chronic Disease; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Male; Pancreatic Hormones; Pancreatitis; Ursodeoxycholic Acid

1997